Law360 has named Williams & Connolly among its 2025 “Intellectual Property Groups of the Year.”  According to the publication, this annual series honors the attorney teams behind litigation wins and significant transaction work that resonated throughout the legal industry this past year.
 
In profiling the firm’s practice, Law360 highlighted a number of significant wins over the past year, including a first-of-its-kind trial victory on behalf of Regeneron adverse to Mylan in its BPCIA patent litigation concerning Regeneron’s market-leading and vision-saving biologic product, Eylea®, as well as first-of-its-kind preliminary injunctions in BPCIA litigation regarding Eylea® against three biosimilar manufacturers.  In addition, Williams & Connolly also protected Pfizer in challenges to its COVID-19 treatment Paxlovid and mRNA vaccine Comirnaty® and successfully represented Bayer CropScience and Monsanto in three inter partes review proceedings against their competitor Corteva Agriscience, where the PTAB found all 93 challenged claims to be unpatentable.
 
To read Williams & Connolly’s “Intellectual Property Group of the Year” profile, click here.